earnings
confidence high
sentiment positive
materiality 0.75
Agile Therapeutics Q1 net revenue $5.7M (+58% QoQ); GAAP net income of $1.3M
AGILE THERAPEUTICS INC
2024-Q1 EPS reported
$0.28
revenue$5,716,000
- Net revenue $5.7M (+58% QoQ, +50% YoY); GAAP net income $1.3M ($0.28/share) vs. net loss $4.5M in Q4 2023.
- Twirla demand 81,088 cycles (+18% QoQ, +80% YoY); factory sales 70,662 cycles (+3% QoQ, +63% YoY).
- Operating expenses $6.8M (-20% YoY); cash $2.6M as of March 31, 2024.
- Stock now trading on OTC market under symbol AGRX; exploring strategic opportunities.